President Trump’s outline is largely an exercise in thinking out loud since it can’t propel anything consequential without legislative action in Congress. Still, the plan—and the reactions it’s eliciting—warrant a look. 

The insurer is planning to reduce reimbursement timelines for hospitals in Oklahoma, Idaho, Minnesota and Missouri from 30 days to 15. The details are unclear, but the company said the framework could extend nationwide.

CMS has made it a priority to increase payments for procedures performed by office-based labs and ambulatory surgical centers. This was reflected in policy changes made as part of the 2026 Medicare Physicians Fee Schedule.

This is a cash and stock transaction that values Penumbra at $374 per share. The move helps Boston Scientific expand its vascular and neurovascular portfolios, gaining new treatments for pulmonary embolism, stroke, deep vein thrombosis and many other critical cardiovascular conditions. 

The company currently has an FDA-cleared cardiac MRI platform but is looking to further its reach into other anatomies, such as the brain, prostate and spine.

Rural hospitals face greater challenges than their metropolitan counterparts in keeping medical equipment operational, because there's rarely a vendor technician around when they need one. 

As of January 3, 2026, data from the Centers for Medicare & Medicaid Services shows that, while 22.8 million Americans used Affordable Care Act exchanges to buy medical coverage, that’s 1.2 million fewer enrollees than last year. 

The device at the heart of this transaction is the PerQseal Elite system, a fully bioabsorbable patch for percutaneous vessel closure. The technology has already gained key approvals in Europe.